Fibrinogen Deposition on Silicone Oil-Infused Silver-Releasing Urinary Catheters Compromises Antibiofilm and Anti-Encrustation Properties
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Slippery silicone-oil-infused (SOI) surfaces have recently emerged as a promising alternative to conventional anti-infection coatings for urinary catheters to combat biofilm and encrustation formation. Benefiting from the ultralow low hysteresis and slippery behavior, the liquid-like SOI coatings have been found to effectively reduce bacterial adhesion under both static and flow conditions. However, in real clinical settings, the use of catheters may also trigger local inflammation, leading to release of host-secreted proteins, such as fibrinogen (Fgn) that deposits on the catheter surfaces, creating a niche that can be exploited by uropathogens to cause infections. In this work, we report on the fabrication of a silicone oil-infused silver-releasing catheter which exhibited superior durability and robust antibacterial activity in aqueous conditions, reducing biofilm formation of two key uropathogens Escherichia coli and Proteus mirabilis by ∼99%, when compared with commercial all-silicone catheters after 7 days while remaining noncytotoxic toward L929 mouse fibroblasts. After exposure to Fgn, the oil-infused surfaces induced conformational changes in the protein which accelerated adsorption onto the surfaces. The deposited Fgn blocked the interaction of silver with the bacteria and served as a scaffold, which promoted bacterial colonization, resulting in a compromised antibiofilm activity. Fgn binding also facilitated the migration of Proteus mirabilis over the catheter surfaces and accelerated the deposition and spread of crystalline biofilm. Our findings suggest that the use of silicone oil-infused silver-releasing urinary catheters may not be a feasible strategy to combat infections and associated complications arising from severe inflammation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Urinary Tract Infections Management · Pelvic floor disorders treatments · Urinary Bladder and Prostate Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Queen’s University Belfast, BT9 7BL, Belfast, United Kingdom
School of Life Sciences, University of Dundee, DD1 5EH, Dundee, United Kingdom
School of Mechanical and Aerospace Engineering, Queen’s University Belfast, BT9 AG, Belfast, United Kingdom
State Key Laboratory of Heavy Oil Processing, Beijing Key Laboratory of Oil and Gas Pollution Control, China University of Petroleum, Beijing102249, China
School of Science and Engineering, University of Dundee, DD1 4HN, Dundee, United Kingdom
References (36)
Show source-provided references
1. 10.1016/S0094-0143(21)00276-710.1016/S0094-0143(21)00276-7 ↗
2. 10.1016/j.ajic.2003.08.00510.1016/j.ajic.2003.08.005 ↗
3. 10.1021/acsbiomaterials.9b0007110.1021/acsbiomaterials.9b00071 ↗
4. 10.1016/j.actbio.2016.11.07010.1016/j.actbio.2016.11.070 ↗
5. 10.1016/S0140-6736(12)61380-410.1016/S0140-6736(12)61380-4 ↗
6. 10.1097/00001432-200502000-0000710.1097/00001432-200502000-00007 ↗
7. 10.1021/acsabm.9b0081410.1021/acsabm.9b00814 ↗
8. 10.1073/pnas.120197310910.1073/pnas.1201973109 ↗
9. 10.1038/nature1044710.1038/nature10447 ↗
10. 10.1021/acsami.1c1453310.1021/acsami.1c14533 ↗
11. 10.1021/acsami.1c1819010.1021/acsami.1c18190 ↗
12. 10.1016/j.jhin.2020.07.01110.1016/j.jhin.2020.07.011 ↗
13. 10.1021/acsami.6b1521310.1021/acsami.6b15213 ↗
14. 10.1002/adfm.20150552210.1002/adfm.201505522 ↗
15. 10.7554/eLife.7579810.7554/eLife.75798 ↗
16. 10.1016/j.apsusc.2020.14767510.1016/j.apsusc.2020.147675 ↗
17. 10.1021/acsami.6b0987910.1021/acsami.6b09879 ↗
18. 10.1046/j.1464-410X.2002.02560.x10.1046/j.1464-410X.2002.02560.x ↗
19. 10.1002/jbm.b.3023010.1002/jbm.b.30230 ↗
20. 10.1016/j.jhin.2019.02.01210.1016/j.jhin.2019.02.012 ↗
21. 10.1093/jac/dkn03410.1093/jac/dkn034 ↗
22. 10.1021/acsbiomaterials.8b0132010.1021/acsbiomaterials.8b01320 ↗
23. 10.1038/nature1044710.1038/nature10447 ↗
24. 10.1016/j.jcis.2021.09.18310.1016/j.jcis.2021.09.183 ↗
25. 10.1016/j.juro.2016.01.10010.1016/j.juro.2016.01.100 ↗
26. 10.1038/nrmicro343210.1038/nrmicro3432 ↗
27. 10.1126/scitranslmed.300938410.1126/scitranslmed.3009384 ↗
28. 10.1016/j.xphs.2019.05.01810.1016/j.xphs.2019.05.018 ↗
29. 10.1016/j.vibspec.2012.04.00610.1016/j.vibspec.2012.04.006 ↗
30. 10.1002/jps.2032110.1002/jps.20321 ↗
31. 10.1039/b719371h10.1039/b719371h ↗
32. 10.1128/CMR.00019-0710.1128/CMR.00019-07 ↗
33. 10.1128/IAI.71.6.3607-3613.200310.1128/IAI.71.6.3607-3613.2003 ↗
34. 10.1093/annhyg/mei01910.1093/annhyg/mei019 ↗
35. 10.1038/sj.eye.670296210.1038/sj.eye.6702962 ↗
36. 10.3390/ma1501026910.3390/ma15010269 ↗